Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific (NYSE: TMO) has announced a 10-year virtual power purchasing agreement (VPPA) with X-ELIO for the Lorca solar project, expected to be operational in early 2026. The company's 73 MW portion will generate approximately 150,000 megawatt-hours of renewable electricity annually, equivalent to powering 40,500 European homes for a year.
This agreement, combined with the previously announced Serbal solar project, will enable TMO to match all its addressable European sites with 100% renewable electricity. The project advances the company's goal of achieving 80% global renewable electricity by 2030. The agreement includes a cohort of pharmaceutical partners (GSK, Gilead Sciences, and Haleon) through the Energize initiative, helping reduce both Scope 2 and Scope 3 emissions.
TMO serves as the cohort lead for this agreement, which aligns with its commitment to reach net-zero emissions by 2050 and its goal to reduce Scope 1 and 2 emissions by 50% by 2030 against a 2018 baseline.
Thermo Fisher Scientific (NYSE: TMO) reported strong Q4 2024 results with revenue growing 5% to $11.40 billion and adjusted EPS increasing 8% to $6.10. Full-year 2024 revenue remained flat at $42.88 billion, while full-year adjusted EPS grew 1% to $21.86.
The company launched several innovative products in 2024, including the Iliad Electron Microscope, Stellar mass spectrometer, and Dionex Inuvion Ion Chromatography system. During Q4, they introduced the iCAP MX Series ICP-MS platform and new additions to the Gibco CTS Detachable Dynabeads platform.
TMO completed the acquisition of Olink and returned $4.6 billion to shareholders through stock buybacks and dividends. The company's Q4 2024 GAAP operating margin improved to 17.7% from 17.0% year-over-year, while adjusted operating margin increased to 23.9% from 23.4%.
Thermo Fisher Scientific (NYSE: TMO) announced that its Olink® Explore Platform has been selected for the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The project aims to analyze over 5,400 proteins from 600,000 samples to discover new protein biomarkers for disease prediction, diagnosis, and treatment.
The project, a collaboration between UK Biobank and 14 leading biopharmaceutical companies, builds on a 2023 pilot project that analyzed 54,000 samples. The study is scheduled to begin in Q1 2025, with data releases starting in 2026 and full dataset availability in 2027. Initially, the project will analyze 300,000 samples, with plans to secure additional funding for another 300,000 samples.
The pilot study's research, published in Nature, has already been cited over 400 times, demonstrating its significant impact on understanding disease development and advancing targeted treatments. One study identified protein risk factors for certain cancers up to seven years before diagnosis.
Thermo Fisher Scientific (NYSE: TMO) has announced that Marc N. Casper, chairman, president and chief executive officer, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 11:15 a.m. (EST). Interested parties can access the webcast through the Investors section of Thermo Fisher's website at www.thermofisher.com.
Thermo Fisher Scientific (NYSE: TMO) has announced it will release its Q4 and full-year 2024 financial results before market opening on Thursday, January 30, 2025. The company will host a conference call at 8:30 a.m. EST to discuss financial performance and future expectations.
Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 internationally, using access code 706921. The call will also be available on the company's website investor section. A replay will be accessible through February 14, 2025, under the News, Events & Presentations section.
Thermo Fisher Scientific (NYSE: TMO) has announced the completion of a $1 billion share repurchase program, which resulted in the buyback of 1.9 million shares of its common stock. As of December 3, 2024, the company maintains $3 billion in remaining authorization for future share repurchases.
Thermo Fisher Scientific (NYSE: TMO) announced that its Board of Directors has authorized a new $4 billion share repurchase program. The program, which has no expiration date, will allow the company to buy back shares through open market or negotiated transactions. This new authorization replaces the existing program, which had $1 billion remaining.
Thermo Fisher Scientific (NYSE: TMO) has announced that their chairman, president and CEO Marc N. Casper will deliver a presentation at the Wolfe Healthcare Conference. The presentation is scheduled for Tuesday, November 19, 2024, at 8:00 a.m. EDT. Interested parties can watch the live webcast through the Investors section of Thermo Fisher's website.
Thermo Fisher Scientific (NYSE: TMO) has announced its Board of Directors has approved a quarterly cash dividend of $0.39 per common share. The dividend will be paid on January 15, 2025, to shareholders who are on record as of December 13, 2024.
Thermo Fisher Scientific (NYSE: TMO) reported Q3 2024 financial results with revenue of $10.60 billion, flat compared to $10.57 billion in Q3 2023. GAAP EPS was $4.25, down from $4.42, while adjusted EPS reached $5.28, compared to $5.69 in the prior year. The company's operating margin decreased to 17.3% from 17.6% year-over-year.
The quarter featured launches of innovative products, including the Iliad scanning transmission electron microscope and MagMAX Sequential DNA/RNA kit. Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07 and maintained revenue guidance of $42.4-$43.3 billion.